ISSN:
1432-1041
Keywords:
Nalbuphine
;
Cerebrospinal fluid pressure
;
opioid antagonists
;
carbon dioxide
;
volunteers
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary We have carried out a double-blind randomized study of the effect of nalbuphine (0.2 mg·kg−1 i. v.) or placebo on mean lumbar cerebrospinal fluid (CSF) pressure, mean cerebral perfusion pressure (CPP), transcutaneous PCO 2 (tcPCO 2), mean arterial blood pressure (MAP), and heart rate (HR) in 10 spontaneously breathing volunteers using invasive CSF pressure measurement. Nalbuphine increased CSF pressure from 9.2 mm Hg to 16.4 mm Hg and decreased CPP from 83.6 mm Hg to 74.4 mm Hg without significantly changing tcPCO 2, MAP, or heart rate. In the placebo group there were no significant changes in CSF pressure, CPP, tcPCO 2, MAP, or heart rate. These findings suggest that nalbuphine should be used with caution in patients at risk of intracranial hypertension.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01740670
Permalink